How Is Hypertension Treated? Lifestyle and Medications

Hypertension treatment rests on two pillars used together: lifestyle changes that can lower blood pressure on their own in mild cases, and medications chosen from several well-studied drug classes when those changes are not enough. Most people with persistently elevated readings end up on at least one drug, and many need two or more. But the lifestyle piece is not a polite suggestion before the “real” treatment begins. Dietary shifts and regular exercise produce blood pressure drops large enough to rival a single medication, and they work alongside drugs to bring readings down further than pills alone.

Dietary Changes That Actually Move the Needle

The single best-studied eating pattern for blood pressure is the DASH diet, which emphasizes fruits, vegetables, whole grains, and low-fat dairy while limiting saturated fat, red meat, and added sugars. In people with stage 1 isolated systolic hypertension, the DASH diet lowered systolic pressure by about 11 mm Hg compared with a typical American diet, and roughly three-quarters of participants brought their systolic reading below 140 mm Hg.¹ Multiple clinical trials, including the PREMIER trial and the OmniHeart trial, have confirmed DASH’s blood-pressure-lowering ability.²

Sodium restriction amplifies those benefits. The landmark DASH-Sodium trial showed that combining the DASH diet with low sodium intake lowered systolic blood pressure by about 11.5 mm Hg in people who already had hypertension, compared with a typical diet with high sodium.³ The relationship between sodium and blood pressure appears roughly linear: the more you cut, the more pressure drops, with no clear floor below which further reduction stops helping.⁴ A large systematic review of randomized trials estimated that each meaningful step down in daily sodium was associated with about a 1 mm Hg drop in systolic pressure, with bigger reductions for bigger cuts.⁵ These effects hold across ethnic groups and in both people with and without existing hypertension, though those who already have high blood pressure see steeper drops.⁶

One practical trick that has gained traction is swapping regular table salt for a potassium-enriched salt substitute. These products typically replace about a quarter of the sodium chloride with potassium chloride. Pooled data show that salt substitutes lower systolic pressure by roughly 5 to 6 mm Hg on average.⁷ A large cluster-randomized trial in rural China found that using a salt substitute reduced rates of stroke, major cardiovascular events, and death compared with regular salt.⁸ The caveat is that people with advanced kidney disease who already have trouble excreting potassium should check with their doctor before switching, since the extra potassium can accumulate.

Exercise and Alcohol

Aerobic exercise remains the most reliably supported physical activity for lowering blood pressure. An eight-week aerobic training program reduced daytime systolic pressure by about 7 to 8 mm Hg and also brought down central aortic blood pressure, a measure of the pressure your heart and brain actually see.⁹ ¹⁰ You may have heard that isometric handgrip exercises lower blood pressure. Some early studies were promising, but controlled comparisons have not confirmed a lasting benefit; in one trial, isometric handgrip training actually raised sleep diastolic pressure slightly. Aerobic activity — walking, cycling, swimming at moderate intensity — is still the exercise modality with the strongest evidence.

Alcohol is another lever. Among people who drink three or more drinks per day, cutting back is associated with meaningful blood pressure drops. A meta-analysis found that heavy drinkers who reduced intake by about half saw systolic drops of roughly 3 to 5 mm Hg on average, with even larger reductions in those who drank six or more per day.¹¹ Complete abstinence from heavy drinking for just one month dropped 24-hour systolic pressure by about 7 mm Hg, and the proportion of heavy drinkers who met criteria for hypertension fell from 42% to 12%.¹² For light drinkers having one or two drinks a day, reducing intake further does not clearly change blood pressure. The message is practical: if you drink heavily, cutting back is one of the most powerful non-drug things you can do.

Sleep Apnea as a Hidden Driver

Obstructive sleep apnea is underrecognized as a contributor to blood pressure that does not respond to standard treatment. During each apnea episode, oxygen dips and the nervous system spikes, repeatedly nudging pressure upward overnight. Treating moderate-to-severe sleep apnea with continuous positive airway pressure (CPAP) leads to substantial reductions in both day and night blood pressure. One study found a drop in mean blood pressure of about 10 mm Hg, which researchers estimated could translate into a 37% reduction in coronary heart disease risk and a 56% reduction in stroke risk.¹³ The effect depends on actually using the CPAP consistently, and partial treatment (reducing apnea episodes by only half) did not move the needle on blood pressure.¹⁴ If your blood pressure stays stubbornly high despite medications and lifestyle changes, untreated sleep apnea is one of the first things to investigate.

First-Line Medication Classes

When lifestyle modifications are not enough on their own, guidelines worldwide recommend starting with one or more drugs from four well-established classes. Each works differently, which is why combining them often works better than pushing a single drug to higher doses.

Thiazide diuretics: These have been used for over 50 years and remain among the most commonly prescribed blood pressure drugs. They act on the kidneys to reduce fluid volume, though their long-term blood-pressure-lowering effect likely involves direct relaxation of blood vessels as well.¹⁵ Common examples include hydrochlorothiazide, chlorthalidone, and indapamide.
ACE inhibitors: Drugs like lisinopril and ramipril block an enzyme that narrows blood vessels. They also boost certain protective molecules, which gives them extra benefits for the heart and kidneys beyond simple blood pressure lowering.¹⁶ A persistent dry cough is the most well-known side effect.
ARBs (angiotensin receptor blockers): Drugs like losartan and valsartan work on the same hormonal system as ACE inhibitors but at a different point. They block the receptor where the blood-vessel-narrowing hormone does its work. ARBs also increase blood flow through the kidneys and reduce protein leakage into urine, making them especially useful when kidney protection is a priority.¹⁷ They generally cause fewer side effects than ACE inhibitors and are the usual swap if the cough is intolerable.
Calcium channel blockers: Amlodipine and nifedipine are probably the best-known examples. These drugs prevent calcium from entering the smooth muscle cells that wrap around arteries, which relaxes those vessels and lowers pressure.¹⁸ Ankle swelling is the most common complaint.

The Beta-Blocker Debate

Beta-blockers (like atenolol, metoprolol, and bisoprolol) have had a bumpy ride in guidelines. Several guideline panels downgraded them from first-line status over the past decade or so, based largely on two comparison trials suggesting they were slightly less protective against stroke than other drug classes. But the 2023 European Society of Hypertension guidelines broke with that trend and put beta-blockers back alongside the other four classes as a first-choice option.¹⁹ The reasoning is that beta-blockers lower blood pressure just as effectively as the other classes, they have solid placebo-controlled evidence for reducing cardiovascular events and death, and the unfavorable comparison data came from only a couple of trials rather than a consistent pattern.²⁰

In practice, beta-blockers are particularly attractive for people who have a resting heart rate above 80 bpm, coronary artery disease, or heart failure, since those conditions benefit from slowing the heart. The current ESH guidelines specifically support their use in patients with a high resting heart rate, which signals overactive sympathetic nervous system activity.²¹ So whether beta-blockers are “first-line” depends on which guideline your doctor follows and whether you have one of those overlapping conditions.

Why Most People End Up on More Than One Drug

Starting two drugs at once rather than slowly escalating a single medication has become increasingly mainstream. A trial in patients with stage 2 hypertension (readings around 160/100 or higher) found that starting with combination therapy produced significantly greater systolic blood pressure reductions than monotherapy across every subgroup examined.²² A large UK real-world study confirmed this: patients started on two-drug therapy were about 17% more likely to reach their blood pressure target, and those on an ACE inhibitor plus a calcium channel blocker specifically were 27% more likely to reach control.²³

Speed matters. A European observational study found that people started on a two-drug fixed-dose combination had a 21% lower risk of cardiovascular hospitalization within the first year than those started on a single agent, and for those who did develop cardiovascular events during follow-up, event rates were 56% lower if they were on combination therapy at the time.²⁴ The American Heart Association has endorsed single-pill combinations (two drugs in one tablet) as a way to simplify treatment, lower pill burden, and overcome the inertia that sometimes prevents doctors from adding a second agent.²⁵ Studies confirm that people prescribed a single pill containing two drugs generally stick with treatment better than those given the same drugs as separate tablets.²⁶

Resistant Hypertension and Spironolactone

About 10 to 15% of people with hypertension have resistant disease, meaning their blood pressure remains above target despite three drugs at adequate doses, one of which is typically a diuretic. For those patients, spironolactone has emerged as the add-on drug of choice. A large crossover trial called PATHWAY-2 found that spironolactone lowered home systolic blood pressure by about 9 mm Hg more than placebo and by roughly 4 mm Hg more than the average of two other add-on options (doxazosin and bisoprolol).²⁷ A systematic review and meta-analysis of multiple trials confirmed substantial reductions in both office and 24-hour ambulatory blood pressure, with spironolactone outperforming alternative add-on drugs as well as placebo.²⁸ In a dedicated study of patients with confirmed resistant hypertension, 24-hour systolic blood pressure dropped by about 16 mm Hg, and nearly half the participants reached controlled ambulatory readings. That effect persisted at a median follow-up of 15 months.²⁹ Spironolactone’s main downsides are breast tenderness in men, the risk of elevated potassium (especially in people with kidney disease), and the need for periodic blood tests to monitor electrolytes.

Hypertension During Pregnancy

Treating blood pressure during pregnancy comes with a narrower toolbox, because many standard drugs (ACE inhibitors, ARBs, most diuretics) are unsafe for the developing fetus. Three medications have the longest safety track records in pregnancy: methyldopa, labetalol, and nifedipine. Pharmacokinetic reviews have found no fetal accumulation with any of these three.³⁰

Labetalol and nifedipine are the two most commonly used options for chronic hypertension in pregnancy, and a large U.S. comparative study found them essentially equivalent in effectiveness and safety: about 42% of women in the labetalol group and 44% in the nifedipine group had the primary effectiveness outcome, with no meaningful difference in rates of small-for-gestational-age babies.³¹ However, a separate target-trial emulation from the UK found that nifedipine was associated with a 33% higher risk of a composite of serious maternal complications, including eclampsia, HELLP syndrome, and renal failure requiring dialysis, compared with labetalol.³² The two studies used different designs and populations, so the question is not fully settled, but labetalol remains the more commonly chosen first option in many settings.

Kidney Disease and Diabetes

When hypertension coexists with chronic kidney disease or diabetic kidney disease, drug selection is not just about blood pressure numbers. Protecting the kidneys from further damage becomes a parallel goal. ACE inhibitors and ARBs are the backbone of treatment here because they reduce the pressure inside the kidney’s filtering units and decrease protein leakage into the urine, both markers of progressive kidney injury.¹⁷ UK guidelines for diabetic kidney disease recommend a renin-angiotensin system blocker as the first medication for most patients, with newer drug classes such as SGLT2 inhibitors and nonsteroidal mineralocorticoid antagonists layered on in selected individuals for additional kidney and cardiovascular protection.³³ ³⁴ Combining an ACE inhibitor and an ARB simultaneously is generally avoided because trials showed it increased the risk of kidney injury and dangerously high potassium without extra cardiovascular benefit.

Treating Older Adults Without Overdoing It

In people over 65, the benefits of treating hypertension are well established, but the risks of pushing blood pressure too low are also real. The SPRINT trial randomized participants to intensive versus standard blood pressure targets. Intensive treatment was tied to a higher risk of serious hypotension events (about 67% more likely) and possibly syncope, though interestingly it did not increase the rate of falls.³⁵ Older age, frailty, and chronic kidney disease all raised the risk of hypotension and syncope regardless of treatment intensity. In a separate study of older adults with hypertension, the use of diuretics specifically was associated with about a 2.8-fold higher odds of falls, though the number of antihypertensive drugs overall was actually associated with fewer falls, possibly reflecting better overall management.³⁶ The practical takeaway for older patients: the drugs work, but blood pressure targets may need to be a bit more relaxed in frail individuals, and symptoms like dizziness on standing should be reported rather than toughed out.

Does It Matter When You Take Your Pills?

For years, some clinicians advised patients to take at least one blood pressure medication at bedtime, hoping to improve overnight blood pressure control and reduce cardiovascular risk. A 2024 randomized trial (the OMAN trial) did find that bedtime dosing lowered nighttime systolic blood pressure about 3 mm Hg more than morning dosing, with better nocturnal blood pressure control rates.³⁷ But does that translate into fewer heart attacks and strokes? The BedMed trial, which followed patients for a median of 4.6 years, found no difference. The rate of cardiovascular events and death was essentially identical whether medications were taken in the morning or at bedtime.³⁸ The conclusion: take your medication whenever you are most likely to remember it. The time of day does not appear to change your long-term risk.

Why People Stop Taking Their Medications

Hypertension is often called a “silent” condition because it typically causes no symptoms until something goes wrong. That silence is a major reason people stop taking their pills. A meta-integration of qualitative research identified several recurring barriers: a reduced sense of benefit (people feel fine without treatment), difficulty adapting to the patient role, limited access to healthcare, and gaps in medication literacy.³⁹ A comprehensive review categorized non-adherence factors into five domains: sociodemographic factors like income and literacy; healthcare system factors like the patient-clinician relationship; therapy-related factors such as complex regimens and side effects; condition-related factors including depression and substance use; and patient-related factors like fear of dependence or denial of the diagnosis.⁴⁰ This is where single-pill combinations and home blood pressure monitoring have practical value: fewer pills to remember and visible feedback that the treatment is doing something both help people stay on track. One randomized trial found that patients who used home blood pressure monitoring with telemetric reporting to their clinician achieved better blood pressure control than those managed by office visits alone.⁴¹

Renal Denervation for Drug-Resistant Cases

For patients who cannot tolerate enough medications or whose blood pressure resists maximal drug therapy, catheter-based renal denervation is an emerging option. The procedure uses a catheter threaded into the kidney arteries to disrupt the nerve signals that keep blood pressure high. A 2025 network meta-analysis of multiple sham-controlled trials found that two specific approaches — radiofrequency ablation with a bifurcation catheter and ultrasound-based denervation — produced significant ambulatory systolic reductions of about 4 to 6 mm Hg compared with a sham procedure.⁴² Those numbers are modest, but for someone already on four or five medications, any additional drop counts.

The durability question is important. A 10-year follow-up of patients who underwent renal denervation for resistant hypertension found sustained reductions of about 16 mm Hg in 24-hour ambulatory systolic blood pressure, with no increase in the number of blood pressure medications over time. Kidney function declined only within the expected range for aging, and no serious device-related complications emerged over the decade.⁴³ Renal denervation is not a replacement for medications for most people, but for the subset with truly treatment-resistant hypertension, it provides a promising additional tool with a reassuring long-term safety profile so far.